BioSpace News Archive

XERMELO is a first-in-class treatment option for patients whose refractory carcinoid syndrome diarrhea is inadequately controlled with somatostatin analogue (SSA) therapy alone2

Deployment of the scheduling solution across the CareMount Medical network will enhance patient access while automating scheduling protocols

Joint solution enables the young at heart to be proactive in their health and remain independent longer with a flexible solution that supports personal health, safety and wellbeing

Ehave, Inc. announced today that its Board of Directors, supported by its management team, has engaged in a process of exploring strategic alternatives focused on enhancing shareholder value.

HAP is ready for the Medicare Annual Enrollment season with more affordable Medicare Advantage plans to help Michigan’s 2.1 million Medicare beneficiaries get the best care for their health care dollar. Medicare Annual Enrollment starts on Oct. 15 and runs through Dec. 7, 2018.

United Neuroscience, Ltd. today announced five executive appointments as part of the company’s continued expansion of the management team.

Grant Will Help Accelerate Treatment Innovations for Joint Disease

VPOR Discusses Positive Effect Of U.S. Government Reclassifying CBD Enhanced Products From Schedule 1 to Schedule 3; Pending International Distribution Deals

Heska Corporation plans to announce its third quarter 2018 financial results in a press release on Tuesday, November 6, 2018 before the market opens and to host a conference call on the results at 9 a.m. MT / 11 a.m. ET on the same day.

eFFECTOR Therapeutics, Inc. today announced it has entered into a clinical collaboration agreement with Merck (known as MSD outside the United States and Canada), through a subsidiary, to evaluate the combination of eFFECTOR’s tomivosertib (eFT508), an oral, small molecule inhibitor of MNK1/2, with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), for the treatment of patients with metastatic triple negative breast cancer (TNBC).